Phase III, randomized, open-label study of durvalumab (MEDI4736) monotherapy, or durvalumab + tremelimumab, versus standard of care (SoC), in recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): eagle

Eitemau Tebyg

• Phase II, randomized, open-label study of durvalumab (MEDI4736) or tremelimumab monotherapy, or durvalumab + tremelimumab, in patients with recurrent or metastatic (R/M) squamous cell carcinoma of the head and neck (SCCHN): CONDOR
  gan: Gilbert, Jill, et al.
  Cyhoeddwyd: (2015)
• Phase III, randomized, open-label study of durvalumab (MEDI4736) in combination with tremelimumab or durvalumab alone versus platinum-based chemotherapy in first-line treatment of patients with advanced/metastatic NSCLC: MYSTIC
  gan: Rizvi, Naiyer, et al.
  Cyhoeddwyd: (2015)
• Safety and efficacy of durvalumab (MEDI4736) in various solid tumors
  gan: Yang, Hui, et al.
  Cyhoeddwyd: (2018)
• A Phase I study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) in combination with tremelimumab in patients with advanced solid tumors
  gan: Papadopoulos, Kyriakos P, et al.
  Cyhoeddwyd: (2015)
• Phase Ib/II study to evaluate the safety and antitumor activity of durvalumab (MEDI4736) and tremelimumab as monotherapy or in combination, in patients with recurrent or metastatic gastric/gastroesophageal junction adenocarcinoma
  gan: Kelly, Ronan J, et al.
  Cyhoeddwyd: (2015)